Build status - In Progress

Immune Impact of Bevacizumab in Patients with Recurrent Glioblastoma

Recruiting
99 years or below
All
40 participants needed
1 Location

Brief description of study

PURPOSE/DESCRIPTION: Primary: to perform high-dimensional flow cytometry on peripheral blood of patients with recurrent glioblastoma receiving standard of care anti-VEGF therapy with bevacizumab to understand the immune impact of the drug on various immune cell populations. Secondary: To perform an evaluation of ex vivo cytokine production in peripheral blood T Cells for IL-2, IFN-gamma, and TNF-alpha after PMA/ionomycin or CD 3+ stimulation. To perform intracellular measurement of TOX transcription factor levels in peripheral blood immune cells Expression level of surface markers on peripheral blood immune cells before and after bevacizumab therapy 1. Ex-vivo cytokine production after stimulation 2. Intra cellular TOX protein levels

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 17 Jan 2023. Study ID: 848487

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center